Objective: This study aims to determine the survival of prostate cancer (PCa) patients who did not undergo radical prostatectomy, but received hormonal therapy or a combination of radiotherapy and hormonal therapy. Material & Methods: This study was an observational analytic study with a retrospective cohort design, using secondary data to determine baseline data and diagnosis of patients, and using primary data to determine the survival of prostate cancer patients who received combination hormonal and radiotherapy therapy compared with hormonal therapy alone. The analysis was performed using chi-square and contingency coefficients to assess the relationship between survival with factors such as age, stage T, N, M, clinical stage, type of therapy, and prognosis. It also used the Kaplan Maeier curve to assess the survival picture of prostate cancer patients at Sardjito General Hospital. Results: 79 patients met the inclusion criteria. The mean age of the patients was 68 ± 8.4 years. A total of 52 (65.8%) patients received hormonal therapy, and 27 (34.2%) patients received combination hormonal and radiotherapy. There were 41 (51.9%) patients remain life, while 38 (48.1%) of patients died during the monitoring. We found that the Gleason score, PSA level, and clinical stage were significantly associated with patient survival with p <0.005. The 5 years survival rate patient with local, locally advanced clinical stage and PSA level ≤20 ng/ml who received combination hormonal and radiotherapy achieved 100%. Conclusion: Combination of hormonal and radiotherapy was more improving patient survival compared with hormonal therapy only in patient with locally advanced clinical stage, PSA level ≤20 ng/ml and Gleason score ≤7.
radiotherapy, prostate cancer, survival
Abouassaly et al. Epidemiology, etiology, and prevention of prostate cancer. Dalam: Campbell-Walsh Urology Tenth Edition. Philadephia: Saunders. 2012. p. 2690.
Mottet N, Schalken JA, Heidenreich A, et al. Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. Eur Urol Suppl. 2008; 7(6): 460-476.
Umbas Rainy, Hardjowijoto Sunaryo, Mochtar Chaidir A, Safriadi Ferry, Djatisoesanto Wahjoe, Soedarso MA, Danarto, Sihombing Aaron Tigor. Guideline on prostate cancer. Indonesian Urological Association, 2011.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. Jpn J Clin Oncol. 2015; 45(8): 708-712.
Yuri P, Wangge G, Abshari F, et al. Indonesian prostate cancer risk calculator (IPCRC): An application for predicting prostate cancer risk-(a multicenter study). BJU Int. 2014; 114: 19.
Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011; 80(4): 1056-1063.
James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: Data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015; 67(6): 1028-1038.
Mottet N et al. Guideline on prostate cancer. European Urological Association. 2015.
Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79(5): 1310-1317.
Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014; 15(4): 464-473.
Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet. 2011; 378(9809): 2104-2111.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:1081-7.
Kemenkes. Panduan Penanganan Kanker Prostat. Pandu Penanganan Kanker Prostat. 2015. p. 1-10.
Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in Gleason score 7 prostate cancer in Korean men: Significance of the primary Gleason grade. Korean J Urol. 2012;53(12):826-829. doi:10.4111/kju.2012.53.12.826.
Moon SJ, Park SY, Lee TY. Predictive factors of Gleason score upgrading in localized and locally advanced prostate cancer diagnosed by prostate biopsy. Korean J Urol. 2010; 51(10): 677-682.
Nakamura K, Mizowaki T, Imada H, et al. External-beam radiotherapy for localized or locally advanced prostate cancer in Japan: A multi-institutional outcome analysis. Jpn J Clin Oncol. 2008; 38(3): 200-204.
Supit W, Mochtar CA, Santoso RB, Umbas R. Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia. Prostate Int. 2013; 1(1): 16-22.
Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373(9660): 301-308.
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012; 118(12): 3062-3070.
Brassell SA, Rice KR, Parker PM, et al. Prostate Cancer in Men 70 Years Old or Older, Indolent or Aggressive: Clinicopathological Analysis and Outcomes. J Urol. 2011; 185(1): 132-137.
Massengill J, Sun L, Moul J, et al. Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated With Radical Prostatectomy. J Urol. 2003; 169(5): 1670-1675.
Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011; 117(13): 2883-2891.